Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAINASDAQ:CMPSNASDAQ:GLUENYSEAMERICAN:XTNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIatai Life Sciences$2.02-18.5%$1.86$1.03▼$2.64$496.84M1.471.73 million shs4.68 million shsCMPSCOMPASS Pathways$2.35-49.2%$4.08$2.25▼$8.54$433.19M2.251.07 million shs35.84 million shsGLUEMonte Rosa Therapeutics$4.64+0.2%$4.49$3.21▼$12.40$284.79M1.411.08 million shs467,974 shsXTNTXtant Medical$0.59-1.5%$0.59$0.33▼$0.83$83.46M-0.18121,080 shs40,675 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIatai Life Sciences-18.55%-9.82%-1.94%+28.66%+50.75%CMPSCOMPASS Pathways-49.24%-49.35%-46.10%-23.45%-62.34%GLUEMonte Rosa Therapeutics+0.22%-3.73%+16.88%-18.17%+27.82%XTNTXtant Medical-1.50%-5.22%-19.92%+22.92%-13.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIatai Life Sciences2.8309 of 5 stars3.73.00.00.02.41.70.6CMPSCOMPASS Pathways2.2481 of 5 stars3.43.00.00.01.90.80.6GLUEMonte Rosa Therapeutics2.2811 of 5 stars3.41.00.00.00.03.30.6XTNTXtant Medical2.7567 of 5 stars3.55.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIatai Life Sciences 3.33Buy$8.67329.04% UpsideCMPSCOMPASS Pathways 2.86Moderate Buy$17.00623.40% UpsideGLUEMonte Rosa Therapeutics 2.75Moderate Buy$15.50234.05% UpsideXTNTXtant Medical 3.00Buy$1.50154.24% UpsideCurrent Analyst Ratings BreakdownLatest XTNT, ATAI, CMPS, and GLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025CMPSCOMPASS PathwaysEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ In-Line$11.00 ➝ $6.005/27/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$12.005/20/2025ATAIatai Life SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.005/20/2025ATAIatai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/13/2025ATAIatai Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.003/28/2025CMPSCOMPASS PathwaysCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIatai Life Sciences$310K1,305.44N/AN/A$0.69 per share2.93CMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/AGLUEMonte Rosa Therapeutics$75.62M3.77N/AN/A$3.63 per share1.28XTNTXtant Medical$117.27M0.70N/AN/A$0.31 per share1.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIatai Life Sciences-$149.27M-$0.91N/AN/AN/AN/A-102.10%-77.55%8/12/2025 (Estimated)CMPSCOMPASS Pathways-$155.12M-$1.99N/AN/AN/AN/A-81.75%-59.42%7/30/2025 (Estimated)GLUEMonte Rosa Therapeutics-$72.70M$0.0858.01N/AN/A3.86%2.65%1.65%8/14/2025 (Estimated)XTNTXtant Medical-$16.45M-$0.13N/A∞N/A-9.81%-27.01%-12.49%8/6/2025 (Estimated)Latest XTNT, ATAI, CMPS, and GLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ATAIatai Life Sciences-$0.19-$0.15+$0.04-$0.15N/A$1.56 million5/8/2025Q1 2025CMPSCOMPASS Pathways-$0.47-$0.44+$0.03-$0.24N/AN/A5/8/2025Q1 2025GLUEMonte Rosa Therapeutics-$0.24$0.57+$0.81$0.57$13.57 million$84.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIatai Life SciencesN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/AXTNTXtant MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIatai Life Sciences0.084.074.07CMPSCOMPASS Pathways0.1110.1810.18GLUEMonte Rosa TherapeuticsN/A5.615.61XTNTXtant Medical0.512.341.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIatai Life Sciences28.41%CMPSCOMPASS Pathways46.19%GLUEMonte Rosa Therapeutics79.96%XTNTXtant Medical69.33%Insider OwnershipCompanyInsider OwnershipATAIatai Life Sciences26.80%CMPSCOMPASS Pathways3.93%GLUEMonte Rosa Therapeutics6.50%XTNTXtant Medical9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIatai Life Sciences80200.34 million146.65 millionOptionableCMPSCOMPASS Pathways12093.56 million89.89 millionOptionableGLUEMonte Rosa Therapeutics9061.51 million57.51 millionOptionableXTNTXtant Medical120139.32 million125.81 millionNot OptionableXTNT, ATAI, CMPS, and GLUE HeadlinesRecent News About These CompaniesXtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest UpdateJune 15, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Stock Price Crosses Above 200-Day Moving Average - Should You Sell?June 7, 2025 | marketbeat.comXtant Medical Holdings Inc Share Price (XTNT.US)June 4, 2025 | lse.co.ukXtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Drop in Short InterestJune 2, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above 200 Day Moving Average - Here's WhyMay 31, 2025 | marketbeat.comXtant Medical Announces the Launch of OsteoFactor Pro™May 28, 2025 | prnewswire.comXtant Medical (NYSEAMERICAN:XTNT) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?May 24, 2025 | marketbeat.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comXtant Medical Holdings, Inc.: Xtant Medical Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finanznachrichten.deXtant Medical Holdings Inc (XTNT) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...May 13, 2025 | finance.yahoo.comXtant Medical outlines 8–11% revenue growth target for 2025 as company completes vertical integration and launches new productsMay 13, 2025 | msn.comXtant Medical Holdings, Inc. (XTNT) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comXtant Medical Reports First Quarter 2025 Financial ResultsMay 12, 2025 | prnewswire.com6XTNT : A Glimpse of Xtant Medical Hldgs&#...May 9, 2025 | benzinga.comXtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025May 6, 2025 | prnewswire.comWhy Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Up 6.27%April 29, 2025 | aaii.comXtant Medical Launches Trivium™ Advanced Bone Graft for Superior PerformanceApril 23, 2025 | prnewswire.comXtant Medical secures investor support, projects Q1 revenue growthApril 18, 2025 | uk.investing.comXtant Medical sees Q1 revenue $32.8M-$33.1M, two estimates $30.65MApril 17, 2025 | markets.businessinsider.comXtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%April 16, 2025 | prnewswire.comWhy Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Down 14.76%April 10, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTNT, ATAI, CMPS, and GLUE Company Descriptionsatai Life Sciences NASDAQ:ATAI$2.02 -0.46 (-18.55%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.11 +0.09 (+4.46%) As of 06/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.COMPASS Pathways NASDAQ:CMPS$2.35 -2.28 (-49.24%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.53 +0.18 (+7.66%) As of 06/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Monte Rosa Therapeutics NASDAQ:GLUE$4.64 +0.01 (+0.22%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$4.64 0.00 (0.00%) As of 06/23/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Xtant Medical NYSEAMERICAN:XTNT$0.59 -0.01 (-1.50%) Closing price 06/23/2025 04:10 PM EasternExtended Trading$0.60 +0.01 (+2.03%) As of 06/23/2025 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
